Role of P53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy.
Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.
Piperno
G
G
Department of Pathology, Regina Elena Cancer Institute Rome, Italy.
Cosimelli
M
M
Perrone
Donnorso R
DR
Mancini
R
R
Buglioni
S
S
Novelli
F
F
Sperduti
I
I
Zerbini
V
V
Garufi
C
C
Mottolese
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D012004:Rectal Neoplasms / Q000737:chemistry / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53